100 top cell and gene therapy companies to watch in 2023

[Image courtesy of ipopba/Adobe Stock]

The cell and gene therapy sector is poised to deliver a wave of new therapies that could potentially cure rare and common diseases. As many as 13 new cell or gene therapies could be approved for use in the U.S., Europe, or both by the end of 2023.

While manufacturing and regulatory challenges remain, the cell and gene therapy industry continues to offer significant therapeutic potential and commercial opportunities.

This year, we have beefed up our list of leading cell and gene therapy companies, doubling the number of organizations from 50 to 100.

In selecting the companies for this list, we weighed public companies’ degree of involvement in cell and gene therapy, including drug developers, equipment vendors and CDMOs specializing in the area. For private companies, we factored in their funding levels, pipeline and degree of history for the list.


Read more
  • 0

Fujifilm to aquire Atara’s T-cell manufacturing facility in California for $100M

Atara Biotherapeutics announced yesterday that Fujifilm will acquire its T-cell operations and manufacturing (ATOM) facility for $100 million.

South San Francisco-based Atara entered into a long-term strategic agreement with Fujifilm’s Diosynth Biotechnologies (FDB) subsidiary under which Fujifilm will acquire the ATOM facility in Thousand Oaks, Calif., and retain current manufacturing and quality staff at the site.

The deal also includes a long-term supply agreement that could extend to 10 years. After the transaction completes — which is expected to happen in April 2022 — FDB will provide Atara with access to the capacity and capability needed to manufacture clinical and commercial-stage allogeneic cell therapies for its pipeline. FDB will also expand the use of the manufacturing site and use its staff to manufacture a broader portfolio of cell therapies, according to a news release.

Atara’s pipeline includes tabelecleucel (tab-cel),which i…

Read more
  • 0